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DISCUSSION
Dr Brothers. Certainly, we do approach things a little bit
differently down in the Low Country compared with our es-
teemed sister institution up in the Piedmont. I would also argue
that our patients may be somewhat different as well. Clearly, this
number of 206 patients over a 20-month period does not
encompass all of the patients we see in consultation. In fact,
most of the patients that we see in consultation are referred
through the inpatient or direct referral hospital transfer, so that
is probably is why many patients that we intervene on were not
included in this study. Second, within the screening group, I
would also mention that one of the requirements was the
perceived ability for our patients to be able to understand
abstract concepts about what we were doing and cooperate with
the touch screen. Many of our patients were perhaps deemed
unable to understand and cooperate with these requirements.
Regarding whether we have altered our indications for angio-
plasty in response to this study, our group has become much
more willing to consider angioplasty and other methods of
endovascular revascularization compared with the practices de-
scribed in this cohort recruited approximately 5 years ago. I
certainly am in agreement that trying to ascertain SF-36 data or
other disease-specific assessments of quality of life can be quite
complex in these patients, but I do not share your pessimism
that there is little benefit from an attempt to do so. In fact, I
think it is vital that as we look at the results our interventions,
whatever they may be, we continue to pay particular attention to
the patients’ quality of life, not just some other measure that
makes us feel justified as interventionalists, such as patency or
limb salvage, but rather how the patients feel about what we
have been able to help them accomplish.
INVITED COMMENTARY
Michael P. Lilly, MD, Baltimore, Md
The authors are to be commended for applying decision
analysis to the vexing problem of how to measure the efficacy of
treatment for symptomatic lower extremity atherosclerosis and for
the choice to include in this analysis the majority of such patients—
those with milder symptoms. Despite the limited data available to
calibrate the outcome-based probability parameters, the authors’
model was fairly accurate in predicting the quality of life (QOL)
and walking status of patients at 1 year. The truly disappointing
findings were the actual QOL data: (1) significant benefit was
noted only for those with the most severe disease who had surgical
intervention and (2) medical therapy had no impact on QOL
metrics. While one can quibble about whether other QOL ques-
tionnaires may have shown different results in this cohort, the data
are sobering. Data like these have led health care payers, regulatory
agencies, and patients themselves to question the efficacy of man-
agement approaches crafted over decades by vascular specialists.
They also challenge our claim to superior knowledge and expertise
in this arena.
How should vascular surgeons respond? First, we must accept
that our traditional objective end points of patency, ankle pressure,
and rates of limb salvage and survival may not capture the out-
comes most important to our patients, especially those with mild
disease. Second, we must be committed to prospective analysis of
outcomes of our patients with lower extremity atherosclerosis
across the full spectrum of disease and apply the most modern
methods of analysis to this task. The authors point out that better
risk-adjusted outcomes data are needed to more accurately cali-
brate models such as theirs. It may be that accurate prospective
QOL data on percutaneous treatments will provide a valid ratio-
nale for the application of these techniques to subsets of patients
with earlier stages of disease. Third, we must take an active role in
the development and testing of new methods of treatment for
patients with mild disease. The ineffectiveness of current noninter-
ventional therapy from the patient’s perspective is clear from this
study. Finally, vascular surgeons must be open to the idea of
incorporating data from a model such as this into actual clinical
decisionmaking. Such an application is premature at this point, but
data-driven management protocols or guidelines are on the way,
and vascular experts must contribute fundamentally to their devel-
opment for the benefit of both our patients and our specialty.
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